CN1288755A - Pure beta ray corrying safe microball and its preparation - Google Patents
Pure beta ray corrying safe microball and its preparation Download PDFInfo
- Publication number
- CN1288755A CN1288755A CN 00125741 CN00125741A CN1288755A CN 1288755 A CN1288755 A CN 1288755A CN 00125741 CN00125741 CN 00125741 CN 00125741 A CN00125741 A CN 00125741A CN 1288755 A CN1288755 A CN 1288755A
- Authority
- CN
- China
- Prior art keywords
- safe
- beta ray
- microball
- pure beta
- corrying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000005250 beta ray Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- 239000011806 microball Substances 0.000 title claims 6
- 239000004005 microsphere Substances 0.000 claims abstract description 79
- 239000011521 glass Substances 0.000 claims abstract description 58
- 239000011248 coating agent Substances 0.000 claims abstract description 28
- 238000000576 coating method Methods 0.000 claims abstract description 28
- 238000005260 corrosion Methods 0.000 claims abstract description 20
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 11
- OERNJTNJEZOPIA-UHFFFAOYSA-N zirconium nitrate Chemical compound [Zr+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O OERNJTNJEZOPIA-UHFFFAOYSA-N 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 230000032683 aging Effects 0.000 claims description 5
- BNGXYYYYKUGPPF-UHFFFAOYSA-M (3-methylphenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].CC1=CC=CC(C[P+](C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 BNGXYYYYKUGPPF-UHFFFAOYSA-M 0.000 claims description 4
- 229910010413 TiO 2 Inorganic materials 0.000 claims description 4
- 238000001879 gelation Methods 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000004017 vitrification Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 13
- 201000011510 cancer Diseases 0.000 abstract description 11
- 230000007797 corrosion Effects 0.000 abstract description 11
- 238000004090 dissolution Methods 0.000 abstract description 10
- 238000001959 radiotherapy Methods 0.000 abstract description 7
- 230000004913 activation Effects 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 230000002285 radioactive effect Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 238000003904 radioactive pollution Methods 0.000 abstract description 2
- 238000004088 simulation Methods 0.000 abstract description 2
- 238000007654 immersion Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000003980 solgel method Methods 0.000 abstract 1
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000008279 sol Substances 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 239000006087 Silane Coupling Agent Substances 0.000 description 3
- FPCJKVGGYOAWIZ-UHFFFAOYSA-N butan-1-ol;titanium Chemical compound [Ti].CCCCO.CCCCO.CCCCO.CCCCO FPCJKVGGYOAWIZ-UHFFFAOYSA-N 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical class [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
- GFQQCHBYZVGLSY-UHFFFAOYSA-N [Al+3].[Y+3].[O-][Si]([O-])([O-])[O-] Chemical compound [Al+3].[Y+3].[O-][Si]([O-])([O-])[O-] GFQQCHBYZVGLSY-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 239000005336 safety glass Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000005368 silicate glass Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000004544 sputter deposition Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glass Compositions (AREA)
Abstract
载有纯β射线的安全微球及其制备方法,涉及一种载有经活化能产生治癌用的纯β射线的玻璃微球及工艺。由载有纯β射线的玻璃微球、及其采用溶胶凝胶方法涂覆在其外表面上的耐蚀涂层复合而成。本发明的最大优点是放射性同位素不易沥析游移到血液中,经体外生理模拟液浸泡试验,其相应核素的溶出率比无耐蚀涂层微球的核素的溶出率降低1~2个数量级,也无放射性污染,化学稳定性高,制备本发明的工艺简单,操作安全可靠。可广泛用于内放疗治癌。
The safety microsphere loaded with pure beta ray and its preparation method relate to a glass microsphere loaded with pure beta ray for curing cancer by activation energy and its technology. It is composed of glass microspheres loaded with pure β-rays and a corrosion-resistant coating coated on its outer surface by a sol-gel method. The greatest advantage of the present invention is that the radioactive isotope is not easy to leach and migrate into the blood, and the dissolution rate of the corresponding nuclide is 1-2 times lower than that of the nuclide without the anti-corrosion coating microsphere through the immersion test of the in vitro physiological simulation solution. order of magnitude, no radioactive pollution, high chemical stability, simple preparation process and safe and reliable operation. It can be widely used in internal radiation therapy to treat cancer.
Description
本发明涉及一种化学稳定性高的载有经活化能产生治癌用的纯β射线的玻璃微球及其工艺。The invention relates to a glass microsphere with high chemical stability loaded with pure beta ray for cancer treatment through activation energy and its technology.
开刀、化疗和放疗为传统的治癌方法。众所周知,放疗因其针对性和灵活性比化疗更大,癌症患者更愿意用放疗来直接治疗,使肿瘤缩小获得开刀机会,或使肿瘤细胞完全杀尽坏死。尽管癌细胞比正常细胞更容易吸收射线,但是,正常细胞毕竟还是受到射线的伤害。所以体外放疗的射线剂量一般都不大,不足以杀伤所有癌细胞,因此也影响了疗效。八十年代初,国外开始了介入性内放射疗法,将能放出射线的同位素与高分子树脂络合在一起,然后将其介入到体内肿瘤部位。但实际使用时发现,放射性核素与高分子结合得不牢,易脱落成离子状态,流向全身各部位,造成了更大的危害。Surgery, chemotherapy and radiotherapy are traditional cancer treatment methods. As we all know, radiotherapy is more targeted and flexible than chemotherapy. Cancer patients are more willing to use radiotherapy for direct treatment, so that the tumor can be shrunk to obtain a chance of surgery, or the tumor cells can be completely killed and necrotic. Although cancer cells absorb radiation more easily than normal cells, normal cells are still damaged by radiation after all. Therefore, the radiation dose of external radiotherapy is generally not large enough to kill all cancer cells, thus affecting the curative effect. In the early 1980s, interventional internal radiation therapy was started abroad, in which isotopes capable of emitting radiation were complexed with polymer resins, and then inserted into the tumor site in the body. However, in actual use, it was found that the combination of radionuclides and macromolecules is not strong, and it is easy to fall off into an ion state, which flows to various parts of the body, causing greater harm.
日本专利特开平5-208918公开了一种用离子溅射的方法将放射性同位素磷渗入SiO2玻璃微球外表面层,组成了放射性治疗癌症用的渗磷的玻璃微球。该发明的玻璃微球的表面层的磷容易溶解在血液中,流向全身各部位,造成危害。Japanese Patent Laid-Open No. 5-208918 discloses a method for ion sputtering to infiltrate radioactive isotope phosphorus into SiO 2 glass microsphere outer surface layer to form phosphorus-infiltrated glass microspheres for radiotherapy cancer. The phosphorus in the surface layer of the glass microspheres of the invention is easily dissolved in the blood, and flows to various parts of the whole body, causing harm.
为此,1994年1月5日我国的发明专利CN 1080266 A公开了一种磷32系列玻璃微球。它是用磷酸盐、硅酸镁、硅酸铝等盐类熔炼而成。在1991年美国专利US 5011677公开了高温熔炼成的钇铝硅玻璃微球。上述两个专利的放射性同位素虽然与玻璃体结合得比较牢,但是,共同的缺点是:仍然存在着部分放射性核素自玻璃微球沥析出来的现象,溶解在血液中,带来了对病人健康的危害。For this reason, the invention patent CN 1080266 A of my country on January 5, 1994 discloses a kind of phosphorus 32 series glass microspheres. It is smelted from salts such as phosphate, magnesium silicate, and aluminum silicate. In 1991, U.S. Patent No. 5,011,677 disclosed yttrium-aluminum-silicate glass microspheres formed by high-temperature melting. Although the radioisotopes of the above two patents are relatively firmly combined with the vitreous body, the common disadvantage is that there are still some radioactive nuclides leaching out from the glass microspheres, which dissolve in the blood and bring harm to the patient's health. harm.
本发明的目的在于设计一种放射性核素不易脱落的结构简单、使用安全、经活化成为只载有纯β射线的玻璃微球。本发明的另一个目的是提供一种制造该安全微球的方法The object of the present invention is to design a glass microsphere with simple structure, safe use and activated radionuclide that only carries pure beta rays. Another object of the present invention is to provide a method for manufacturing the safe microspheres
为了实现上述目的,本发明是这样进行的,它是由经活化能载有纯β射线的玻璃微球,及其涂覆在它的外表面上的耐蚀涂层复合而成。耐蚀涂层可以是SiO2、或/和Al2O3、或/和TiO2、或/和ZrO2。载有纯β射线的玻璃微球可以是含Y2O3、SiO2、Al2O3的Y-89玻璃微球,也可以是含P2O5、Al2O3、MgO的P-31玻璃微球。In order to achieve the above object, the present invention is carried out in that it is composed of glass microspheres loaded with pure β-rays through activation energy, and a corrosion-resistant coating coated on its outer surface. The anti-corrosion coating can be SiO 2 , or/and Al 2 O 3 , or/and TiO 2 , or/and ZrO 2 . The glass microspheres loaded with pure β rays can be Y - 89 glass microspheres containing Y 2 O 3 , SiO 2 , Al 2 O 3 , or P- 31 glass microspheres.
制备本发明的微球的步骤是;首先在玻璃微球中加入表面活性剂搅拌,表面活性剂可采用聚乙二醇或硅烷偶联剂,加入的量为每100克玻璃微球中加0.3~0.5克表面活性剂。然后将上述玻璃微球浸泡在能形成耐蚀涂层的由含正硅酸乙酯50-100%、硝酸铝0-30%、钛酸丁酯0-20%、硝酸锆0-30%组成的溶胶溶液中搅拌,使经上述处理过的玻璃微球凝胶化,接着固液分离后经旋风干燥去除有机溶剂,再在室温下陈化20-30天,最后在马弗炉内300-600℃下加热蒸发热处理,使其玻璃化,即制得本发明的表面涂覆耐蚀涂层的安全微球。本发明的玻璃微球经中子激活能载有纯β射线的核素Y-90或P-32,具有对人体所有的癌细胞都产生很强的杀死杀伤能力。The step of preparing microspheres of the present invention is; first add surfactant and stir in glass microspheres, surfactant can adopt polyethylene glycol or silane coupling agent, the amount of adding is to add 0.3 in every 100 grams of glass microspheres -0.5 g of surfactant. Then soak the above-mentioned glass microspheres in an anti-corrosion coating material containing 50-100% ethyl orthosilicate, 0-30% aluminum nitrate, 0-20% butyl titanate, and 0-30% zirconium nitrate. Stir in the sol solution to make the above-mentioned treated glass microspheres gel, then remove the organic solvent by cyclone drying after solid-liquid separation, then age at room temperature for 20-30 days, and finally in the muffle furnace for 300- Heating, evaporating and heat treatment at 600°C to make it vitrified, the safety microspheres coated with anti-corrosion coating on the surface of the present invention are obtained. The glass microsphere of the present invention can carry nuclide Y-90 or P-32 of pure beta ray through neutron activation, and has a strong ability to kill all cancer cells in the human body.
本发明的安全微球的最大的优点是安全可靠,由于在含放射性同位素玻璃微球外表牢固地涂覆了一层耐蚀涂层薄膜,使其具有极其稳定的化学性质,所以放射性同位素不易通过沥析过程游移到血液中,对周围也无放射性污染,具有非常可靠的安全性。The biggest advantage of the safe microsphere of the present invention is that it is safe and reliable. Because the outer surface of the glass microsphere containing radioisotope is firmly coated with a layer of corrosion-resistant coating film, it has extremely stable chemical properties, so radioisotope is not easy to pass through. The leaching process migrates into the blood, and there is no radioactive pollution to the surroundings, which is very reliable and safe.
本发明的安全微球还有一个优点是:在中子照射下,能被激活成含有单一的纯β射线的核素Y-90或P-32,它们能顺利地介入到体内指定部位,经动物实验和医院临床使用,证实了此类微球对人体所有的癌细胞都具有很强的杀死杀伤能力,特别是对肝癌、结肠癌、胰腺癌等格外有效。Another advantage of the safety microspheres of the present invention is that under neutron irradiation, they can be activated into nuclide Y-90 or P-32 containing a single pure beta ray, and they can be smoothly inserted into designated parts of the body. Animal experiments and clinical use in hospitals have confirmed that such microspheres have a strong ability to kill all cancer cells in the human body, especially effective against liver cancer, colon cancer, and pancreatic cancer.
本发明还有一个优点是制备方法简单易控制,用本发明的方法制得的安全微球的耐蚀涂层能牢固地粘附于玻璃微球之表面,涂层不会脱落。耐蚀涂层的组成在中子射线的激活下,不会放射出其他任何长寿命的有害杂质射线。玻璃微球与耐蚀涂层不会发生化学反应而改变各自的特性。放射性核素的溶出率比没有涂覆耐蚀涂层的原玻璃微球的溶出率降低了1~2个数量级。Another advantage of the present invention is that the preparation method is simple and easy to control, and the corrosion-resistant coating of the safety microspheres prepared by the method of the present invention can firmly adhere to the surface of the glass microspheres, and the coating will not fall off. The composition of the corrosion-resistant coating will not emit any other long-lived harmful impurity rays under the activation of neutron rays. The glass microspheres and the corrosion-resistant coating will not chemically react to change their respective characteristics. The dissolution rate of the radionuclides is 1-2 orders of magnitude lower than that of the original glass microspheres without the anti-corrosion coating.
本发明的具体结构和制造方法由以下的实施例及其附图给出。The specific structure and manufacturing method of the present invention are given by the following examples and accompanying drawings.
图1为本发明的结构示意图。Fig. 1 is a structural schematic diagram of the present invention.
图2为本发明的工艺流程图。Fig. 2 is a process flow diagram of the present invention.
下面结合附图对本发明作进一步的描述;Below in conjunction with accompanying drawing, the present invention will be further described;
首先请参阅附图1,本发明的安全微球由能载有纯β射线的玻璃微球1和耐蚀涂层2组成。能载有纯β射线的玻璃微球1可以是含Y2O3、SiO2、Al2O3的Y-89玻璃微球,也可以是含P2O5、Al2O3、MgO的P-31玻璃微球。Please refer to accompanying
接着请参阅附图2,本发明的制备安全微球的方法如下:首先将玻璃微球1放入容器中,喷洒入0.3~0.5克表面活性剂聚乙二醇或硅烷偶联剂,搅拌,使之湿润完成预处理3。然后将上述玻璃微球1浸泡在由正硅酸乙酯50-100%、硝酸铝0-30%、钛酸丁酯0-20%、硝酸锆0-30%组成的溶胶溶液的容器内,置于磁力搅拌器上,搅拌,进行玻璃微球表面包敷凝胶处理4。接下去进行固液分离5。再下去将玻璃微球1和40-60℃热风同方向进入旋风干燥器进行干燥6,去除部分有机溶剂后使湿凝胶变为干凝胶。室温下陈化20-30天,使凝胶稳定7。最后在马弗炉内300-600℃下加热蒸发热处理8,使其玻璃化,形成SiO2、或/和Al2O3、或/和TiO2、或/和ZrO2耐蚀涂层2的本发明的安全微球。Then please refer to accompanying
实施例1:Example 1:
将100克含有Y2O3、SiO2、Al2O3的Y-89玻璃微球1置于容器内,加入0.4克的硅烷偶联剂表面活性剂,搅拌完成预处理3,然后浸泡在含100%正硅酸乙酯溶液溶胶中,放在磁力搅拌台上,搅拌进行凝胶化包敷处理4,然后固液分离5,将涂覆好的玻璃微球取出,在旋风干燥器进口与同方向进入的干燥的热风一起进行旋风干燥6,去除部分有机溶剂后,室温下陈化25天时间,使其聚合稳定7,最后在马弗炉内500-600℃下加热蒸发热处理8,使其玻璃化,即制得本发明的表面有SiO2涂层的含钇安全微球。这种安全玻璃微球的直径在20~60μm范围内。涂有SiO2涂层的这种玻璃微球在生理模拟液中30天钇的溶出率为9.0×10-7g/g,而原玻璃微球的溶出率为3.6×10-5g/g,降低了2个数量级。本发明的玻璃微球经中子激活能载有纯β射线的核素Y-90,具有对人体所有的癌细胞都产生很强的杀死杀伤能力。Put 100 grams of Y-89
实施例2:Example 2:
将100克含有P2O5、Al2O3、MgO的P-31玻璃微球1在0.5克聚乙二醇,搅拌,使之湿润,完成预处理3。然后将上述玻璃微球1浸泡在能形成耐蚀涂层2的由含正硅酸乙酯80-90%、硝酸铝10-20%组成的溶胶溶液中搅拌,进行凝胶化包敷处理4,经上述处理过的玻璃微球凝胶物质,进行固液分离5,将涂覆溶胶的玻璃微球1取出,在旋风干燥器进口与同方向进入的干燥的40-60℃热风一起进行旋风干燥6,去除部分有机溶剂后室温下陈化30天时间,使其聚合稳定7,最后在马弗炉内400-500℃下加热蒸发热处理8,使其玻璃化,得到表面有SiO2和Al2O3涂层的含磷安全微球。这种安全微球的直径在15~55μm范围内。涂有SiO2和Al2O3涂层的这种玻璃微球在生理模拟液中30天磷的溶出率为2.2×10-5g/g,原玻璃微球的溶出率为7.9×10-3g/g,降低了1~2个数量级。100 grams of P-31
实施例3:Example 3:
将100克含有P2O5、Al2O3、MgO的P-31玻璃微球1在0.5克聚乙二醇,搅拌,使之湿润,完成预处理3。然后将上述玻璃微球1浸泡在能形成耐蚀涂层2的由含正硅酸乙酯80-95%、钛酸丁酯5-20%组成的溶胶溶液中搅拌,进行凝胶化包敷处理4,经上述处理过的玻璃微球凝胶物质,进行固液分离5,将涂覆溶胶的玻璃微球1取出,在旋风干燥器进口与同方向进入的干燥的40-60℃热风一起进行旋风干燥6,去除部分有机溶剂后室温下陈化30天时间,使其聚合稳定7,最后在马弗炉内400-500℃下加热蒸发热处理8,使其玻璃化,得到表面有SiO2和TiO2涂层的含磷安全微球。这种安全微球的直径在15~55μm范围内。涂有SiO2和TiO2涂层的这种玻璃微球在生理模拟液中30天磷的溶出率为5.3×10-5g/g,原玻璃微球的溶出率为7.9×10-3g/g,降低了1~2个数量级。100 grams of P-31
实施例4:Example 4:
将100克含有P2O5、Al2O3、MgO的P-31玻璃微球1在0.5克聚乙二醇,搅拌,使之湿润,完成预处理3。然后将上述玻璃微球1浸泡在能形成耐蚀涂层2的由含正硅酸乙酯80-95%、硝酸锆5-20%组成的溶胶溶液中搅拌,进行凝胶化包敷处理4,经上述处理过的玻璃微球凝胶物质,进行固液分离5,将涂覆溶胶的玻璃微球1取出,在旋风干燥器进口与同方向进入的干燥的40-60℃热风一起进行旋风干燥6,去除部分有机溶剂后室温下陈化30天时间,使其聚合稳定7,最后在马弗炉内400-500℃下加热蒸发热处理8,使其玻璃化,得到表面有SiO2和ZrO2涂层的含磷安全微球。这种安全微球的直径在15~55μm范围内。涂有SiO2和ZrO2涂层的这种玻璃微球在生理模拟液中30天磷的溶出率为6.4×10-6g/g,原玻璃微球的溶出率为7.9×10-3g/g,降低了3个数量级。100 grams of P-31
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001257412A CN1141146C (en) | 2000-10-20 | 2000-10-20 | Pure beta ray corrying safe microball and its preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB001257412A CN1141146C (en) | 2000-10-20 | 2000-10-20 | Pure beta ray corrying safe microball and its preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1288755A true CN1288755A (en) | 2001-03-28 |
CN1141146C CN1141146C (en) | 2004-03-10 |
Family
ID=4591525
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB001257412A Expired - Fee Related CN1141146C (en) | 2000-10-20 | 2000-10-20 | Pure beta ray corrying safe microball and its preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1141146C (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1798580B (en) * | 2003-04-04 | 2010-10-13 | 生物领域医疗公司 | Microspheres comprising therapeutic and diagnostic radioactive isotopes |
CN110227170A (en) * | 2018-03-05 | 2019-09-13 | 白金科技股份有限公司 | Radiate microballoon and preparation method thereof |
CN111202871A (en) * | 2018-11-21 | 2020-05-29 | 白金科技股份有限公司 | Radioactive microsphere and radioactive filler composition |
-
2000
- 2000-10-20 CN CNB001257412A patent/CN1141146C/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1798580B (en) * | 2003-04-04 | 2010-10-13 | 生物领域医疗公司 | Microspheres comprising therapeutic and diagnostic radioactive isotopes |
CN110227170A (en) * | 2018-03-05 | 2019-09-13 | 白金科技股份有限公司 | Radiate microballoon and preparation method thereof |
CN111202871A (en) * | 2018-11-21 | 2020-05-29 | 白金科技股份有限公司 | Radioactive microsphere and radioactive filler composition |
Also Published As
Publication number | Publication date |
---|---|
CN1141146C (en) | 2004-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6998105B2 (en) | Low density radionuclide-containing particulate material | |
Chao et al. | Rhenium‐188 Labeled Tungsten Disulfide Nanoflakes for Self‐Sensitized, Near‐Infrared Enhanced Radioisotope Therapy | |
US10940219B2 (en) | Radioactive microspheres made of nanoporous glass for radiation therapy | |
JP2004511576A (en) | Polymer-based radionuclide-containing particulate material | |
TWI675669B (en) | Radiative microsphere and preparation method thereof | |
WO2018028642A1 (en) | Medical iodine-131 carbon microsphere and method for fabrication thereof | |
WO2002034299A1 (en) | Inorganic low density radionuclide coated particles | |
CN1141146C (en) | Pure beta ray corrying safe microball and its preparation | |
Day | Glasses for radiotherapy | |
US7316644B2 (en) | Method for preparing particles of radioactive powder containing Cesium-131 for use in brachytherapy sources | |
JP6901498B2 (en) | Isotope preparation method | |
Atroshchenko et al. | Glassy microspheres and their applications in nuclear medicine | |
Zhou et al. | Clinically translatable phosphonated silica microspheres for selective internal radiation therapy of hepatocellular carcinoma | |
US3719750A (en) | Radioactive preparation absorbable in organism and method of obtaining same | |
US20230050728A1 (en) | Method of manufacturing silica microspheres | |
CN118647414A (en) | Radiotherapy gel and preparation method thereof | |
RU2794457C1 (en) | Method for errlich adenocarcinoma treatment | |
KR20240140920A (en) | Radiotherapy gel and method of making same | |
US20230263913A1 (en) | Radiotherapy gel and method of preparing the same | |
CN115869658B (en) | Separation system for preparing Ra-223, separation method, application and preparation method thereof | |
US20240335573A1 (en) | Radionuclide microspheres and preparation method therefor and application thereof | |
CN117695431A (en) | Embolic microsphere loaded with radiotherapy nuclide and preparation method thereof | |
CN117603460A (en) | A matrix resin and 90Y resin | |
CN116715805A (en) | A multifunctional gel microsphere rich in bisphosphonic acid groups and its preparation method and application | |
Man | Development of Radiopharmaceutical DW-166HC for Anticancer drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Tongji University Document name: Notification to Pay the Fees |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040310 Termination date: 20141020 |
|
EXPY | Termination of patent right or utility model |